PRMT5 and nasopharyngeal carcinoma: To further validate the combinatorial effects of PRMT5 inhibitors (PRMT5i) and paclitaxel in chemoresistant NPC, we conducted colony formation assay (Fig. 2A) and time-course cell proliferation assay (Fig. 2B) in 5-8 F R cells.